epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
tki
given
standard
therapi
nonsmal
cell
lung
cancer
nsclc
patient
carri
activ
mutat
egfr
gene
egfrtki
gefitinib
administ
nsclc
patient
carri
activ
egfr
mutat
eg
delet
exon
exon
significantli
improv
respons
surviv
furthermor
egfr
mutat
predominantli
found
patient
eastasian
origin
howev
although
egfrtki
treatment
signific
effect
respons
prognosi
studi
report
patient
treat
egfrtki
experi
sever
advers
event
treatment
discontinu
patient
unmanag
sever
advers
event
diarrhea
rash
frequent
advers
effect
welltoler
manag
toxic
death
rare
pneumon
emerg
common
sever
form
toxic
account
half
toxic
death
follow
administr
egfrtki
base
retrospect
analysi
japanes
patient
egfrtki
treatmentrel
risk
pneumon
mortal
respect
accord
worldwid
metaanalysi
risk
pneumon
mortal
risk
follow
egfrtki
treatment
incid
rate
egfrtki
treatmentrel
toxic
higher
among
japanes
race
reason
japanes
nsclc
patient
suscept
egfrtkiinduc
pneumon
clear
notabl
incid
pneumon
higher
male
patient
smoke
histori
preexist
interstiti
pneumon
poor
perform
statu
consid
grade
eastern
cooper
oncolog
group
howev
biolog
characterist
associ
egfrtkiinduc
pneumon
yet
determin
egfr
receptor
tyrosin
kinas
belong
erbb
receptor
famili
regul
multipl
aspect
pulmonari
epitheli
cell
homeostasi
respons
injuri
includ
cell
prolifer
cell
surviv
barrier
function
ion
transport
egfr
erbb
famili
member
activ
direct
interact
egflik
ligand
initi
receptor
dimer
increas
kinas
activ
lead
activ
downstream
signal
factor
phosphatidylinositol
akt
mitogen
activ
protein
kinaseextracellularsignalregul
kinas
mapkerk
pathway
addit
egfr
transactiv
variou
extracellular
stimuli
antagonist
g
proteincoupl
receptor
gpcr
cytokin
receptor
tumor
necrosi
factor
tnf
interleukin
il
interferon
ifn
report
transactiv
egfr
pulmonari
epitheli
cell
tumor
necrosi
factor
potent
proinflammatori
cytokin
regul
divers
biolog
process
includ
cell
surviv
apoptosi
prolifer
migrat
variou
kind
tissu
dysregul
tnf
implic
numer
diseas
state
rheumatoid
arthriti
crohn
diseas
ulcer
coliti
cancer
furthermor
neutral
antibodi
tnf
develop
therapeut
autoimmun
inflammatori
diseas
tnf
regul
anti
proapoptot
signal
transduct
pathway
maintain
balanc
two
pathway
tnfinduc
antiapoptot
pathway
includ
erkmapk
nuclear
factor
kappalightchainenhanc
activ
b
cell
wherea
proapoptot
tnf
inducedpathway
includ
mapk
stressactiv
protein
kinasecjun
kinas
sapkjnk
pneumon
inflammatori
cytokin
tnf
granulocytemacrophag
colonystimul
factor
gmcsf
releas
lead
cell
apoptosi
tissu
necrosi
microvascular
dysfunct
sever
egfr
ligand
cleav
cell
surfac
disintegrin
metalloproteinas
domaincontain
protein
also
call
tace
enzym
process
term
ectodomain
shed
tacemedi
releas
egfr
ligand
cell
surfac
via
ectodomain
shed
consid
essenti
egfr
activ
previous
report
egfr
human
epitheli
growth
factor
receptor
transactiv
tnf
promot
surviv
respons
colon
epitheli
cell
tnf
transactiv
requir
srckinas
activ
akt
downstream
target
find
illustr
import
relationship
tnf
egfr
signal
transduct
pathway
role
epitheli
cell
surviv
cytokineenrich
environ
acut
injuri
respons
therefor
hypothes
egfrtki
may
enhanc
develop
lung
injuri
tnfoverexpress
lung
tissu
blockad
tnfinduc
egfr
transactiv
studi
employ
surfact
protein
c
spc
tnf
transgen
tg
mice
gene
place
control
transcript
promot
spc
gene
tnf
express
lung
mice
produc
alveol
alveolar
disrupt
progress
pulmonari
fibrosi
result
demonstr
administr
egfrtki
gefitinib
remark
enhanc
lung
inflamm
spctnf
tg
mice
significantli
induc
apoptosi
pulmonari
cell
via
mapk
pathway
human
lung
epitheli
cell
exhibit
egfr
transactiv
tnf
via
cleavag
heparinbind
hb
egf
tace
therebi
protect
tnfinduc
apoptosi
although
egfrtki
promis
therapeut
egfr
mutationposit
patient
care
administ
patient
accompani
copd
pneumon
pneumonia
enrich
inflammatori
cytokin
egfr
regul
multipl
epitheli
respons
injuri
howev
role
egfr
activ
immunemedi
lung
injuri
examin
address
hypothesi
egfr
tyrosin
kinas
activ
protect
lung
tissu
inflammatori
cytokin
storm
use
spctnf
transgen
mice
increas
express
tnf
type
ii
epitheli
cell
tabl
mice
lymphocyt
fibros
alveol
resembl
mani
aspect
human
sever
emphysema
pulmonari
fibrosi
gefitinib
mgkg
oral
administ
daili
wild
type
wt
spctnf
tg
mice
day
wild
type
wt
mice
signific
patholog
chang
observ
figur
spctnf
tg
mice
administr
gefitinib
result
sever
lymphocyt
infiltr
alveolar
septa
mice
also
develop
thicker
alveolar
septa
nonadminist
mice
figur
day
administr
also
death
relat
gefitinib
administr
moreov
chang
bodi
weight
either
wt
spctnf
tg
mice
figur
determin
inflammatori
cytokin
mediat
lymphocyt
infiltr
spctnf
tg
mice
realtim
rt
pcr
perform
tabl
tabl
wt
mice
although
mrna
level
proinflammatori
cytokin
significantli
increas
inflamm
lung
injuri
observ
suggest
mainten
balanc
antiinflammatori
cytokin
unknown
mechan
mrna
level
found
significantli
increas
gefitinib
administr
taken
togeth
result
suggest
treatment
egfrtki
might
caus
lung
inflamm
spctnf
tg
mice
overexpress
tnf
lung
evalu
extent
gefitinibinduc
inflamm
mous
lung
use
indocyanin
green
icg
load
liposom
label
sialyl
lewi
x
slx
surfac
slxlipoicg
slxlipoicg
could
accumul
region
inflamm
tumor
owe
interact
slx
eselectin
enhanc
eselectin
express
inflammatori
cytokin
tnf
vascular
endotheli
cell
wt
spctnf
tg
mice
measur
wholelung
fluoresc
ex
vivo
use
clairvivo
opt
fluoresc
imag
system
observ
slight
accumul
icgload
liposom
whole
lung
spctnf
tg
mice
treat
gefitinib
compar
whole
lung
wt
mice
furthermor
day
gefitinib
administr
accumul
liposom
enhanc
wholelung
sampl
taken
spctnf
tg
mice
howev
enhanc
liposom
accumul
gefitinib
treatment
wt
mice
figur
b
result
suggest
egfr
tyrosin
kinas
activ
protect
mice
tnfinduc
lung
inflamm
mice
model
tnf
pleiotrop
cytokin
activ
anti
proapoptot
signal
pathway
cell
surviv
determin
balanc
two
pathway
therefor
detect
cell
undergo
apoptosi
situ
oligolig
isol
wt
spctnf
tg
mice
gefitinib
administr
figur
c
gefitinib
administr
significantli
enhanc
apoptosi
lung
epitheli
cell
spctnf
tg
mice
wt
mice
figur
egfr
phosphoryl
pegfr
significantli
increas
spctnf
tg
mice
compar
wt
mice
figur
f
moreov
egfr
tyrosin
kinas
activ
indic
egfr
phosphoryl
significantli
inhibit
spctnf
tg
mice
gefitinib
administr
figur
g
activ
phosphoryl
downstream
signal
akt
also
decreas
spctnf
tg
mice
figur
antiapoptot
respons
mediat
akt
raf
els
activ
phosphoryl
lead
apoptosi
therefor
apoptosi
spctnf
tg
mice
may
induc
mapk
pathway
via
map
kinas
kinas
mkk
addit
inhibit
akt
activ
gefitinib
exposur
figur
determin
mechan
egfr
transactiv
tnf
exposur
lung
epitheli
cell
cell
employ
first
cell
expos
tnf
ngml
min
stimul
egfr
phosphoryl
initi
min
tnf
exposur
figur
moreov
egfr
phosphoryl
enhanc
tnf
dosedepend
matter
figur
tnfinduc
egfr
phosphoryl
inhibit
gefitinib
suggest
necess
egfr
tyrosin
kinas
activ
regard
figur
transfect
small
interf
rna
sirna
egfr
cell
led
decreas
egfr
express
attenu
tnfinduc
egfr
phosphoryl
figur
therefor
tnfinduc
egfr
phosphoryl
requir
express
activ
egfr
interestingli
expos
cell
simultan
tnf
gefitinib
enhanc
tnfinduc
apoptosi
figur
f
result
suggest
egfr
phosphoryl
tnf
inhibit
tnfinduc
apoptosi
tace
facilit
shed
egfr
ligand
avail
bind
stimul
egfr
process
call
autocrin
loop
cell
tace
inhibitor
suppress
tnfinduc
egfr
phosphoryl
egfstimul
figur
furthermor
enhanc
tnfinduc
apoptosi
significantli
figur
c
suggest
tace
mediat
egfr
phosphoryl
lead
cell
surviv
upon
tnf
exposur
major
downstream
signal
egfr
includ
raserk
pathway
tnf
transactiv
egfr
shed
mainli
two
egfr
ligand
determin
signal
molecul
downstream
egfr
regul
cell
surviv
presenc
tnf
use
wortmannin
inhibit
akt
respect
wortmannin
alon
induc
apoptosi
cell
wortmannin
significantli
enhanc
tnfinduc
apoptosi
affect
tnfinduc
apoptosi
figur
e
therefor
pathway
may
contribut
cell
surviv
via
tnfinduc
egfr
transactiv
although
would
difficult
recapitul
spctnf
tg
mous
model
use
cell
specul
signal
contribut
tnfinduc
apoptosi
cetuximab
egfrneutr
antibodi
bind
egfr
downregul
ligandinduc
egfr
phosphoryl
verifi
involv
egfr
ligand
tnfinduc
egfr
transactiv
use
neutral
antibodi
egfr
therefor
tnfinduc
egfr
phosphoryl
inhibit
cetuximab
indic
egfr
ligand
contribut
egfr
transactiv
tnf
figur
identifi
egfr
ligand
involv
tnfinduc
egfr
phosphoryl
neutral
antibodi
employ
shown
figur
egfrtransactiv
tnf
attenu
treatment
neutral
antibodi
hbegf
furthermor
combin
neutral
antibodi
hbegf
exhibit
remark
inhibit
egfr
phosphoryl
presenc
tnf
figur
measur
express
hbegf
cultur
supernat
elisa
perform
hbegf
express
cultur
supernat
increas
upon
tnf
exposur
howev
presenc
reduc
express
egfrligand
figur
e
moreov
knockdown
tace
use
sirna
figur
reduc
amount
hbegf
cultur
supernat
figur
h
result
indic
express
hbegf
cultur
supernat
regul
tace
ligand
involv
tnfinduc
transactiv
cell
taken
togeth
lung
epitheli
cell
protect
tnfinduc
apoptosi
egfr
transactiv
via
autocrin
loop
egfr
ligand
hbegf
cleav
tace
studi
perform
verifi
hypothesi
egfrtki
induc
pneumon
block
egfr
transactiv
tnf
mechan
egfrtkiinduc
pneumon
complet
elucid
howev
studi
provid
evid
egfr
tyrosin
kinas
activ
prevent
lung
injuri
tnfenrich
environ
furthermor
found
lung
epitheli
cell
tace
requir
tnfinduc
egfr
activ
target
egfr
transactiv
find
show
transactiv
egfr
prevent
tnfinduc
lung
epitheli
cell
apoptosi
tnfinduc
egfr
phosphoryl
regul
critic
physiolog
respons
acut
lung
injuri
airway
inflamm
character
releas
proinflammatori
cytokin
tnf
induc
excess
egfr
signal
high
amount
egfr
ligand
amphiregulin
secret
bronchial
epitheli
cell
result
activ
egfr
autocrin
loop
lead
increas
mucu
product
goblet
cell
therefor
inhibit
egfr
tyrosin
kinas
activ
may
benefici
treatment
hypersecretori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
convers
egfrligand
egf
regul
lung
epitheli
cell
repair
vitro
vivo
egfr
overexpress
activ
respons
lung
epitheli
injuri
play
import
role
lung
epitheli
repair
increas
amount
egfr
observ
bleomycininjur
lung
addit
identifi
bronchoalveolar
lavag
fluid
patient
acut
lung
injuri
taken
togeth
express
egfr
egfrligand
egfr
tyrosin
kinas
activ
protect
lung
epitheli
cell
apoptosi
enhanc
recoveri
lung
inflamm
injuri
howev
studi
requir
discov
role
egfr
ligand
inflammatori
lung
diseas
studi
egfr
tyrosin
kinas
transactiv
tnf
spctnf
tg
mice
inhibit
egfr
tyrosin
kinas
gefitinib
increas
tnfinduc
apoptosi
epitheli
cell
significantli
enhanc
lung
injuri
result
studi
consist
previou
report
show
activ
egfr
erbb
famili
member
protect
colon
epitheli
cell
tnfinduc
apoptosi
understand
develop
pneumon
whole
lung
essenti
evalu
lung
inflamm
egfrtki
gefitinib
administr
ex
vivo
region
inflamm
arthriti
tumor
vascular
endotheli
cell
activ
inflammatori
cytokin
tnf
leukocyt
roll
vascular
endotheli
cell
bind
eselectin
vascular
endotheli
cell
surfac
leukocyt
infiltr
vascular
endothelium
migrat
accumul
inflammatori
region
sugar
chain
sialyl
lewi
x
slx
well
character
eselectin
ligand
express
surfac
leukocyt
therefor
slxliposom
primarili
target
eselectin
activ
endotheli
cell
deliv
accumul
icg
content
region
inflamm
within
tumor
therefor
employ
slxlipoicg
evalu
lung
tissu
inflamm
administr
gefitinib
wt
spctnf
tg
mice
basal
accumul
slxlipoicg
spctnf
tg
mice
higher
wt
mice
furthermor
gefitinib
administr
accumul
slxlipoicg
enhanc
spctnf
tg
mice
wt
mice
result
indic
gefitinib
remark
enhanc
tnfinduc
lung
inflamm
spctnf
tg
mice
base
result
significantli
increas
cytokin
gefitinib
treatment
spctnf
tg
mice
appear
act
primarili
nonhematopoiet
cell
endotheli
cell
epitheli
cell
fibroblast
increas
express
link
inflammatori
diseas
asthma
cystic
fibrosi
copd
airway
well
inflammatori
bowel
diseas
appear
play
import
protect
role
infect
iyoda
et
al
report
stimul
phosphoryl
mapk
enhanc
express
cytokin
monocyt
chemoattract
protein
mcp
macrophag
inflammatori
protein
mip
cultur
mous
mesangi
cell
spctnf
tg
mice
gefitinib
treatment
led
increas
phosphoryl
mapk
suggest
may
stimul
mapk
activ
induc
lung
epitheli
cell
apoptosi
metaanalysi
trial
egfr
tki
treatment
lung
cancer
patient
reveal
pneumon
common
caus
death
relat
egfr
tki
toxic
previou
clinic
studi
identifi
risk
factor
egfr
tkiinduc
pneumon
includ
old
age
smoke
histori
preexist
interstiti
lung
diseas
poor
perform
statu
exampl
higher
plasma
concentr
tnf
measur
older
group
younger
group
smoke
may
influenc
tnfmediat
system
inflamm
copd
interstiti
pneumon
furthermor
poorperform
statu
cachexia
associ
cytokin
tnf
well
known
taken
togeth
risk
factor
associ
tnfenrich
lung
condit
therefor
case
egfr
tkiinduc
pneumon
egfr
tyrosin
kinas
activ
may
requir
maintain
homeostasi
tnfrich
lung
environ
chronic
inflamm
present
summari
abl
elucid
molecular
mechan
relat
egfrtkiinduc
lung
injuri
use
spctnf
tg
mice
egfr
activ
prevent
tnfinduc
apoptosi
sever
inflamm
upregul
cytokin
may
involv
furthermor
lung
epitheli
cell
found
tnf
activ
egfr
phosphoryl
stimul
hbegf
via
tace
activ
egfr
transactiv
tnf
regul
cell
surviv
taken
togeth
find
provid
biolog
mechan
underli
egfrtkiinduc
lung
injuri
therefor
find
suggest
caution
taken
prior
administr
egfrtki
nsclc
case
associ
high
level
tnf
inflamm
studi
potenti
limit
effect
report
base
spctnf
tg
mice
highli
express
tnf
whole
lung
howev
exclud
effect
cytokin
signal
transduct
associ
lung
fibrosi
would
address
futur
research
human
recombin
egf
human
recombin
tnf
purchas
peprotech
rocki
hill
nj
usa
gefitinib
kindli
provid
astrazeneca
tokyo
japan
calbiochem
san
diego
ca
usa
follow
antibodi
purchas
cell
signal
technolog
danver
usa
total
egfr
antibodi
phosphoegfr
antibodi
total
akt
antibodi
phosphoakt
antibodi
total
antibodi
antibodi
antibodi
total
mapk
antibodi
mapk
antibodi
tace
antibodi
antibodi
meanwhil
antibodi
specif
total
mkk
purchas
santa
cruz
biotechnolog
dalla
tx
usa
cetuximab
purchas
showa
univers
hospit
shinagawa
tokyo
japan
materi
use
western
blot
analysi
biorad
laboratori
richmond
ca
usa
dulbecco
modifi
eagl
medium
dmem
materi
purchas
sigma
chemic
st
loui
mo
usa
unless
otherwis
state
pharmacolog
inhibitor
agonist
dissolv
dmso
ad
medium
final
dmso
concentr
cell
atcc
american
type
cultur
collect
cell
cultur
collagenco
dish
maintain
dmem
fetal
bovin
serum
fb
uml
penicillin
streptomycin
experi
cell
transfer
dmem
fb
uml
penicillin
streptomycin
h
cell
confluenc
transient
transfect
smartpool
sirna
dharmacon
lafayett
co
nontarget
nt
human
egfr
human
tace
use
lipofectamin
accord
manufactur
instruct
h
transfect
cell
cultur
serumstarv
medium
h
treatment
cell
wash
twice
icecold
pb
scrape
cell
lysi
buffer
nonidet
mm
nacl
mm
trishcl
ph
proteas
phosphatas
ii
iii
inhibitor
cocktail
lysat
incub
ice
min
clarifi
centrifug
rpm
min
protein
content
supernat
determin
bicinchonin
acid
bca
method
equival
amount
protein
mix
laemmli
sampl
buffer
incub
min
sampl
separ
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
gel
transfer
polyvinyliden
fluorid
membran
block
nonfat
dri
milk
trisbuff
salin
tb
mm
tri
mm
nacl
mm
kcl
ph
tween
tbst
h
room
temperatur
membran
expos
primari
antibodi
overnight
follow
manufactur
suggest
dilut
dilut
membran
wash
tbst
expos
secondari
antibodi
dilut
h
tbst
wash
tbst
immunoreact
band
visual
western
lightn
enhanc
chemiluminesc
kit
perkinelm
life
scienc
waltham
usa
densitometr
analysi
perform
use
imagej
softwar
nih
cdna
synthes
total
rna
isol
whole
lung
sampl
analyz
real
time
pcr
use
powerup
sybr
green
mastermix
appli
biosystem
fluorexcencebas
rtpcrdetect
system
geneamp
appli
biosystem
specif
primer
set
shown
supplementari
tabl
gapdh
use
intern
control
pcr
reaction
done
duplic
target
gene
intern
control
rel
gene
express
calcul
accord
method
control
valu
express
anim
experi
perform
accord
protocol
approv
institut
anim
care
use
committe
showa
univers
code
date
april
spctnf
transgen
mice
obtain
masaki
fujita
fukuoka
univers
fukuoka
japan
background
pcr
primer
specif
tnf
sequenc
use
genotyp
describ
miyazaki
et
al
mice
n
per
group
week
old
g
daili
oral
administ
gefitinib
mgkg
mgkg
contain
tween
tween
control
day
lung
tissu
fix
neutralbuff
formalin
paraffinembed
section
lung
tissu
ground
homogen
buffer
lyse
protein
analysi
apoptosi
detect
lung
section
apoptag
peroxidas
situ
oligo
ligat
kit
stain
use
dna
ligas
follow
manufactur
guidelin
merck
millipor
billerica
result
observ
differenti
interfer
contrast
microscopi
rel
apoptosi
determin
least
cell
apoptag
fluorescein
situ
apoptosi
detect
kit
tunel
use
dapi
stain
perform
describ
previous
slide
observ
fluoresc
microscopi
percent
apoptosi
determin
least
cell
human
hbegf
human
cultur
supernat
measur
elisa
r
system
accord
manufactur
instruct
prevent
bind
egf
ligand
egfr
tace
inhibitor
pretreat
min
treat
tnf
ngml
variou
durat
supernat
analyz
elisa
accord
manufactur
recommend
signific
differ
two
group
determin
pair
student
ttest
statist
signific
set
p
experi
repeat
least
three
time
separ
occas
